|
|
Volumn 25, Issue 4, 2007, Pages 365-366
|
|
Pharma consolidates its grip on post-antibody landscape
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIRHEUMATIC AGENT;
BEVACIZUMAB;
MONOCLONAL ANTIBODY;
RANIBIZUMAB;
TRU 015;
UNCLASSIFIED DRUG;
BIOTECHNOLOGY;
DRUG INDUSTRY;
DRUG MANUFACTURE;
DRUG MARKETING;
FOOD AND DRUG ADMINISTRATION;
MEDICAL TECHNOLOGY;
NOTE;
ONCOLOGY;
PHARMACEUTICAL CARE;
PRIORITY JOURNAL;
ANIMALS;
ANTIBODIES;
BINDING SITES, ANTIBODY;
CLINICAL TRIALS;
DRUG DESIGN;
DRUG INDUSTRY;
HUMANS;
MICE;
PROTEIN BINDING;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 34147174947
PISSN: 10870156
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt0407-365 Document Type: Note |
|
Times cited : (26)
|
|
References (0)
|
